Country Application No. Filing Date Status -------------------------------------------------------------------------------- *** *** 11/15/90 *** *** *** *** 11/15/90 pending *** *** 11/15/90 Pending *** *** 11/15/90 Pending *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. APPENDIX II *** *** BACKGROUND *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. *** *** *** SPECIFIC AIMS OF THE RESEARCH PROGRAM *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. *** *** *** REFERENCES *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. APPENDIX III. Collateral Therapeutics Development Plan *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. APPENDIX III. (cont'd) Collateral Therapeutics Development Plan *** *** *** *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. FIRST AMENDMENT TO AGREEMENT This First Amendment to Agreement (hereafter "Amendment") is effective on April 28, 1998 by and between COLLATERAL THERAPEUTICS INC., a corporation organized and existing under the laws of California, having a place of business at 0000 Xxxx Xxxxxx Xxxxx, Xxx Xxxxx, Xxxxxxxxxx 00000 (hereafter "CORPORATION"); and NEW YORK UNIVERSITY, a corporation organized and existing under the laws of the State of New York, having a place of business at ...
Country Application No. Patent No. ------- --------------- ---------- Australia ******* Canada ******* China ******* Denmark ******* Europe ******* (AT, BE, CH, DE, ES, FR, GB, XX, XX, XX, XX, XX xxx SE) Finland ******* Israel ******* Japan ******* Singapore ******* S. Korea ******* Mexico ******* Norway ******* Taiwan ******* USA ******* USA ******* USA ******* EXHIBIT D
Country Application No. Int’l Filing Date Patent Number Grant Date C Oman To Be Filed C Pakistan 115/2021 Feb. 8, 2021 Pending C Panama 9385001 Feb. 8, 2021 Pending C Peru To Be Filed C Philippin es 12022550438 Feb. 8, 2021 Pending C Qatar To Be Filed C Saudi Arabia To Be Filed C Seychell es To Be Filed C Singapor e 11202201400X Feb. 8, 0000 Xxxxxxx X Xxxxx Xxxxxx To Be Filed X Xxxxx Xxxxx Xx Xx Xxxxx X Xxx Xxxxx To Be Filed C Taiwan 110104831 Feb. 8, 0000 Xxxxxxx X Xxxxxxxx 2201001154 Feb. 8, 0000 Xxxxxxx X Xxxxxxxx & Xxxxxx TTA202200022 Feb. 8, 2021 Pending C Ukraine To Be Filed C United Arab Emirates To Be Filed C US 17/170172 Feb. 8, 2021 Pending C Venezuel a 2021-000027 Feb. 8, 0000 Xxxxxxx X Xxxxxxx 1202201444 Feb. 8, 2021 Pending C WO PCT/US2021/01 6984 Feb. 7, 2021 PCT applicatio n D WO PCT/US2021/04 8054 Aug. 27, 2021 PCT applicatio n E WO PCT/US2021/06 4021 Dec. 17, 2021 PCT applicatio n
Country Application No. STATUS/PATENT NO. ------- --------------- ----------------- [*] [*] [*] United States 07/681,551 5,171,739 [*] [*] [*] United States 07/990,662 5,308,834 United States 07/990,044 5,334,584 Australia 88501/91 660427 Canada 2,088,496 Pending EPO 00126715.2 Pending Japan 517796/91 Pending Japan (Div) 2002-108147 3493022 Japan (Div) 2003-317025 Penxxxx Xxxxx 700379/1993 240385 [*] INCYTE 11303 Title: Compositions Comprising a Bactericidal/Permeability-Increasing Protein and a Lipid Carrier, Methods of Making Same, and Uses Thereof. Inventors: Marra, Scott Based on PCT/US92/08234 [WO 93/05797] [*] filed September 00, 0000. XOUNTRY APPLICATION NO. STATUS/PATENT NO. ------- --------------- ----------------- [*] [*] [*] [*] [*] [*] Australia 26997/92 664206 Canada 2,119,262 2,119,262 EPO 93906309.5 0610445 France 93906309.5 0600000 Xxxxxxx 93906309.5 69327516.2 Great Britain 93906309.5 0610445 Ireland 93906309.5 0610445 Switzerland 93906309.5 0610445 [*] [*] [*] INCYTE 11306 Title: Glycosylated and Non-Glycosylated Bactericidal/Permeability- Increasing Protein and Methods for Producing Same. Inventors: Marra, Scott, Lane, Snable COUNTRY APPLXXXXXXX XX. XXXXXX/PATENT NO. ------- --------------- ----------------- [*] [*] [*] [*] [*] [*] [*] [*] [*] EPO 94921451.4 726944 France 94921451.4 726000 Xxxxxxx 94921451.4 69400000 Xxxxxxx 94921451.4 726944 [*] [*] [*] INCYTE 11307 Title: Recombinant Endotoxin-Neutralizing Proteins Inventors: Scott, Marra Based on PCT/US96/06134 [WO 96/34873] which corresponds to X.X. Xxxxxxation No. 08/431,517 filed May 1, 1995. COUNTRY APPLICATION NO. STATUS/PATENT NO. ------- --------------- ----------------- United States 08/431,517 6,265,187 [*] [*] [*] [*] [*] [*] Australia 56358/96 Pending INCYTE 11308 Title: Neutralization of Non-Lipopolysaccharide Compounds by Bactericidal/Permeability-Increasing Protein Inventors: Espevik, Marra COUNTRY APPLICATION NO. STXXXX/PATENT NO. ------- --------------- ----------------- [*] [*] [*] United States 08/267,139 5,532,216 87 INCYTE 11309 Title: Genetically Engineered BPI Variant Proteins Inventors: Scott, Marra COUNTRY APPLICATION NO. XXXXXX/XATENT NO. ------- --------------- ----------------- United States 07/915,720 5,770,694 [*] [*] [*] [*] [*] [*] [*] [*] [*] United States 09/025,543 6,093,801 [*] [*] [*] EXHIBIT B Tab 6
Country Application No. STATUS/PATENT NO. ------- --------------- ----------------- [*] [*] [*] [*] [*] [*] [*] [*] [*] United States 09/881,490 Pending Australia 31981/95 709738 Canada 2,200,069 2,200,069 [*] [*] [*] Hong Kong 98110168.8 Pending Japan 8-510173 Pending United States 08/621,259 5,858,974 United States 09/227,659 6,156,730 United States 09/677,664 6,664,231 [*] [*] [*] [*] [*] [*] [*] [*] [*] PCT US96/03845 Pub. WO97/04008 [*] [*] Tab 42 Title: Therapeutic Peptide-Based Constructs Derived From Domain II of Bactericidal/Permeability-Increasing Protein Inventors: Little, Lin, Gikonyo Based on PCT/US00/17358 [WO01/00655] which corresponds to U.S. Application No. 09/344,219 filed June 25, 1999. COUNTRY APPLICATION NO. STATUS/PATENT NO. ------- --------------- ----------------- United States 09/344,219 6,515,104 [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] Australia 57628/00 Pending Cxxxxx 0,000,000 Xxxxxxx [*] [*] [*] Japan 2001-518656 Pending Tab 43 Title: Derivative Compounds Derived From or Based On Bactericidal/Permeability-Increasing Protein Inventors: Little, Lin, Gikonyo Based on PCT US00/17383 [WO 01/00671] which corresponds to U.S. Application No. 09/344,541 filed June 25, 1999. COUNTRY APPLICATION NO. STATUS/PATENT NO. ------- --------------- ----------------- United States 09/344,541 6,355,616 [*] [*] [*] [*] [*] [*] [*] [*] [*] Tab 44 Title: Therapeutic Derivative Compounds Derived From Domain II of Bactericidal/Permeability-Increasing Protein Inventors: Little, Lin, Gikonyo COUNTRY APPLICATION NO. STATUS/PATENT NO. ------- --------------- ----------------- United States 09/344,827 6,423,825 [*] [*] Exhibit C-1 NYU License Agreement Amendment NYU Acknowledgement ACKNOWLEDGEMENT Reference is made to the Amended and Restated Research and License Agreement dated as of September 1, 1993, as amended (the "License Agreement") between XOMA Corporation and New York University ("NYU") and the Seventh Amendment to License Agreement dated as of the date hereof (the "Amendment" and, together with the License Agreement, the "Agreement") among XOMA Technology Ltd., XOMA Ireland Limited (each a subsidiary of the successor in interest to XOMA Corporation and collectively "XOMA") and NYU. NYU hereby acknowledges to Zephyr Sciences Inc. ("Zephyr") that (i) to the knowledge of its Executive Director, Industrial Liaison/Technology Transfer without investigation, as of the date hereof, there is no breach or event of default existing or continuing by XOMA and (ii) Zephyr is a...
Country Application No. Int’l Filing Date Patent Number Grant Date and Turkey A European Patent Office 21178364.2 Dec. 16, 2015 Pending A Hong Kong 42022050450.0 Dec. 16, 2015 Pending A India 201717025098 Dec. 16, 2015 Pending A Israel 252997 Dec. 16, 2015 IL252997 May 1, 2021 Granted A Israel 279663 Dec. 16, 2015 Pending A Japan 2021-204082 Dec. 16, 2015 Pending A Japan 2017-534192 Dec. 16, 2015 Pending A Singapor e 10202105371Y Dec. 16, 0000 Xxxxxxx X Xxxxx Xxxxxx 2017/04291 Dec. 16, 2015 Pending A South Korea 10-2017- 7020692 Dec. 16, 2015 Pending A US 16/921,359 Dec. 16, 2015 Pending A WO PCT/US2015/06 6144 Dec. 16, 2015 PCT applicatio n B Australia 2018378832 Dec. 7, 2018 2018378832 Sep. 2, 2021 Granted B Australia 2021206866 Dec. 7, 2018 Pending B Brazil BR11202001058 13 Dec. 7, 2018 Pending B Brazil BR12202101262 75 Dec. 7, 0000 Xxxxxxx X Xxxxxx 3,082,191 Dec. 7, 2018 3,082,191 Sept. 21, 2021 Granted B China 201880073278.8 Dec. 7, 0000 Xxxxxxx X Eurasian Patent Office 202091005 Dec. 7, 0000 Xxxxxxx X European Patent Office 18886104.1 Dec. 7, 2018 Pending B Hong Kong 62021026557.0 Dec. 7, 2018 40037053 Dec. 3, 0000 Xxxxxxx X Xxxx Xxxx 62021026723.8 Dec. 7, 2018 Pending B India 202017019418 Dec. 7, 0000 Xxxxxxx X Indonesi a P00202003494 Dec. 7, 2018 Pending B Israel 274155 Dec. 7, 2018 274155 Oct. 30, 2021 Granted B Israel 284100 Dec. 7, 2018 Pending B Japan 2020-524817 Dec. 7, 2018 JP6804790B1 Dec. 7, 2020 Granted B Japan 2020-195927 Dec. 7, 2018 Pending Patents and Patent Applications Ref . Country Application No. Int’l Filing Date Patent Number Grant Date B Japan 2021-106296 Dec. 7, 2018 Pending B Mexico MX/a/2020/0053 92 Dec. 7, 2018 Pending B Philippin es 1-2022-550371 Dec. 7, 0000 Xxxxxxx X Philippin es 1-2020-550607 Dec. 7, 0000 Xxxxxxx X Russian Federatio n 2020116571 Dec. 7, 2018 Pending B Saudi Arabia 520412305 Dec. 7, 0000 Xxxxxxx X Xxxxxxxx e 11202004403Q Dec. 7, 0000 Xxxxxxx X Xxxxx Xxxxxx 2020/02849 Dec. 7, 0000 Xxxxxxx X Xxxxx Xxxxx 10-2020- 7014737 Dec. 7, 2018 00-0000000 Apr. 28, 0000 Xxxxxxx X Xxxxx Xxxxx 10-2021- 7012910 Dec. 7, 0000 Xxxxxxx X Xxxxxx Xxxxxxx XX0000000.6 Dec. 7, 2018 GB2581936 Feb. 10, 0000 Xxxxxxx X Xxxxxx Xxxxxxx GB2020498.8 Dec. 7, 2018 GB2590198 Feb. 23, 2022 Granted B US 17/465,344 Dec. 7, 2018 Pending B US 16/755,779 Dec. 7, 2018 Pending B WO PCT/US2018/06 4503 Dec. 7, 2018 PCT applicatio n C Algeria To Be Filed C Argentin a P210100320 Feb. 8, 2021 Pending C ARIPO APP2022013879 Feb. 8, 2021 Pending C Australia To Be Filed C Bahrain To...
Country Application No. Patent No. Australia 2003218178 Canada 0000000 Xxxxx 3808393 European Patent 3714169.4 Hong Kong 5102043.8 Croatia P20040957A Indonesia W-00200401972 India 2304/CHENP/2004 New Zealand 546789 546789 Poland P-373282 Serbia P-901/04 Russian Federation 2004130461 2323477 South Africa 2004/7341 2004/7341
Country Application No. Patent No. Patent Term Utility Claim Taiwan 092132155 I275591 2003/11/17 ~ 2023/11/16 Organ Damage (Liver, Kidney, Lung Damage) Taiwan 095146643 I430992 2003/11/17 ~ 2023/11/16 Rheumatoid arthritis, Organ damage (Liver or kidney damages), Crohn’s Disease, Ulcerative colitis, Multiple sclerosis Hong Kong 14104476.9 HK1192711 (License out) 官網資訊專利所有人為TAIWANJ PHARMACEUTICALS CO., LTD (2022/4/20瀏覽) 2003/05/16 ~ 2023/05/16 Organ Damage (Liver, Kidney, Lung Damages), Liver damage caused by alcohol abuse, hepatitis, cirrhosis, bacterial infection or environment toxins India 3435/DXXX/2004 IN240229 (License out) 官網沒有從TAIWANJ 讓渡出去的文件 (2022/4/20瀏覽) 2003/05/16 ~ 2023/05/16 Organ Damage (Liver, Kidney, Lung Damages), Liver damage caused by alcohol abuse, hepatitis, cirrhosis, bacterial infection or environment toxins Japan 20040505341 JP5438250 (License out) 官網資訊權利者為タイワンジェ ファーマシュティカルズ カンパニー リミテッド (2022/4/20瀏覽) 2003/05/16 ~ 2023/05/16 Liver and kidney damages associated with overproduction of TNF-α Singapore 2004063871 SG108388 (License out) 官網資訊專利所有人為TAIWANJ PHARMACEUTICALS CO., LTD (2022/4/20瀏覽) 2003/05/16 ~ 2023/05/16 Organ Damage (Liver, Kidney, Lung Damages), Liver damage caused by alcohol abuse, hepatitis, cirrhosis, bacterial infection or environment toxins USA 10/936,431 US 7,923,454 2004/09/08 ~ 2025/01/27 Organ Damage (Liver, Kidney, Lung Damages), Rheumatoid arthritis, Crohn’s Disease, Multiple sclerosis USA 12/400,344 US 8,017,622 2009/03/09 ~ 2023/05/16 Crohn’s Disease, Liver Damage USA 13/228,527 US 9,776,971 2011/09/09 ~ 2023/05/16 Organ Damage (Liver, Kidney Damages), Crohn’s Disease, Pulmonary fibrosis DEFINITIVE AGREEMENT AIH (Autoimmune Hepatitis) Country Application No. Patent No. & Current Status Patent Term Utility Claim Taiwan 105109186 TWI612961 2016/03/24 ~ 2036/03/24 Nalmefene, naltrexone or derivatives thereof for use in treating AILD USA 15/078,342 US 9,757,372 2016/03/23 ~ 2036/03/23 Nalmefene, naltrexone or derivatives thereof for use in treating AILD Australia 20160235093 AU2016235093 2016/03/24 ~ 2036/03/24 Nalmefene, naltrexone or derivatives thereof for use in treating AILD Canada 2983121 CA2983121 2016/03/24 ~ 2036/03/24 Nalmefene, naltrexone or derivatives thereof for use in treating AILD EPO EP16769679.8 EP3273958 (DE, FR, GB) 2016/03/24 ~ 2036/03/24 Nalmefene, naltrexone or derivatives thereof for use in treating AILD Korea 1000000000000 KR10-2064334 (Licensed out) 官網資訊權利所有人為타이완제이 파마슈티컬스 컴퍼니 리미티드(2022/4/20瀏覽) 2016/03/24 ~ 2036/03/24...
Country Application No. (Publication No.)
